Venous thromboembolism (VTE) is a dangerous pulmonary vascular disorder with a high fatality rate and can be effectively treated to reduce morbidity and death rate. Patients with coronavirus disease 2019 have coagulation issues and a proven propensity for thrombosis. We looked for research on VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE) in electronic databases, such as Embase, Cochrane, Scopus, Medline, Google Scholar, clinicaltrials.gov, PubMed, and International Pharmaceutical Abstracts. The considerations for VTE therapy and prevention that may be inferred from the epidemiological data of DVT of the leg, pelvis, or arm, as well as its consequence, PE are the subject of this study. Prevention includes both mechanical and pharmacological methods. Mechanical prophylaxis refers to methods that reduce venous stasis in the lower limbs, such as graded compression stockings and intermittent pneumatic compression devices. Novel oral anticoagulants are currently the most widely used medicines to treat VTE. Other therapeutic options include a vena caval filter and thrombolysis. The purpose of this review is to summarize the pathophysiology, clinical manifestations, prophylaxis, and management of VTE.
Key words: Cardiovascular diseases, Venous thromboembolism, Deep vein thrombosis, Pulmonary embolism, Anticoagulant.
|
